Evidence map›Paper›PMID 39291193›Full record

ArticleKidney international reports2024

Gene Expression Sets and Renal Profiling from the Renal AL Amyloid Involvement and NEOD00 (RAIN) Trial.

Cindy Varga, Felix Eichinger, Viji Nair, Abhijit S Naik, Samih H Nasr, Agnes B Fogo, Denis Toskic, Matthias Kretzler, Raymond L Comenzo

Registry-linked trialAbstract read
In one paragraph

Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03168906 (The RAIN Study, a Multicenter Randomized Double-blind Phase 2b Study of NEOD001 in Previously Treated Subjects With Systemic Light-chain), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03168906 phase2terminatednot on this map

The RAIN Study, a Multicenter Randomized Double-blind Phase 2b Study of NEOD001 in Previously Treated Subjects With Systemic Light-chain (AL) Amyloidosis and Persistent Renal Involvement

TypeinterventionalSponsorTufts Medical CenterRan2017 to 2019Enrolled12ConditionsAmyloidosisArmsNEOD001, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cindy VargaPlasma Cell Disorders Division, Atrium Health Levine Cancer Institute, Charlotte, North Carolina, USA.
Felix EichingerDivision of Nephrology, University of Michigan, Ann Arbor, Michigan, USA.
Viji NairDivision of Nephrology, University of Michigan, Ann Arbor, Michigan, USA.
Abhijit S NaikDivision of Nephrology, University of Michigan, Ann Arbor, Michigan, USA.
Samih H NasrDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Agnes B FogoDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Denis ToskicTufts University School of Medicine, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, Massachusetts, USA.
Matthias KretzlerDivision of Nephrology, University of Michigan, Ann Arbor, Michigan, USA.
Raymond L ComenzoTufts University School of Medicine, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, Massachusetts, USA.

Funding

Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
The Impact of COVID-19 on People Living with Rare Diseases and Their FamiliesU2CTR002818 · NCATS · CINCINNATI CHILDRENS HOSP MED CTR · PI Maurizio Macaluso, Michael Wagner · 2019 to 2026
$51.2M
Training Program in Clinical & Translationa Research in Human Glomerular DiseaseU54DK083912 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KRETZLER, MATTHIAS · 2009 to 2023
$20.3M
University of Michigan O'Brien Kidney Translational Resource Center (MKTC)U54DK137314 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Salim Hayek · 2023 to 2026
$4.7M
Screening for AL Amyloidosis in Smoldering Multiple MyelomaR01CA279808 · NCI · TUFTS MEDICAL CENTER · PI Raymond Luke Comenzo · 2024 to 2026
$2.3M
Defining the molecular landscape of hyperfiltration-mediated glomerular injury using kidney allografts as a model systemK23DK125529 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NAIK, ABHIJIT S · 2021 to 2025
$962k
Screening to Improve Survival in AL AmyloidosisR21AG070502 · NIA · TUFTS MEDICAL CENTER · PI COMENZO, RAYMOND LUKE, LENTZSCH, SUZANNE · 2020 to 2021
$515k
NCATS NIH HHS U2C TR002818NCATS NIH HHS UL1 TR002240NCI NIH HHS R01 CA279808NIA NIH HHS R21 AG070502NIDDK NIH HHS K23 DK125529NIDDK NIH HHS U54 DK083912NIDDK NIH HHS U54 DK137314
6 · The paper itself

Abstract

Introduction: There is an unmet need to understand the mechanisms by which amyloid deposition drives alterations in the kidney. We leveraged renal biopsies from amyloid light-chain (AL) amyloidosis participants of the Renal AL Amyloid Involvement and NEOD00 (RAIN) trial (NCT03168906) to perform transcriptional profiling and to employ a novel histologic scoring tool. Our objective was to utilize a transcriptome-driven approach to identify AL molecular signatures that may be prognostic. Methods: Clinical data were correlated to histologic and molecular findings. A composite scarring injury and amyloid score (AS) were assigned to each biopsy. Glomerular and tubulointerstitial (TI) compartments were microdissected and sequenced separately. Expression data were compared to healthy living donors and focal segmental glomerulosclerosis (FSGS) profiles. Differentially expressed genes were determined. Results: Cluster analysis revealed 2 distinct patient clusters (G1 and G2) based on gene expression. The AS was higher in the TI compartment (6.5 vs. 4.5; Conclusion: Despite the small sample size, we identified 2 distinct groups of patients with AL based on molecular signatures. Detailed studies of a larger cohort encompassing omics technologies at a single cell resolution will further help to identify the response of individual kidney cell types to amyloid deposits, potentially leading to the development of novel therapeutic targets.

Indexed as

AL amyloidosisproteinuriatranscriptional profiling

Identifiers

PMID39291193
PMCPMC11403054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.